Bayer using Accenture’s AI tool to accelerate drug development

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/ipopba)
(Image: Getty/ipopba)

Related tags: Accenture, Data management, Clinical data, Bayer

Bayer collaborates with Accenture on the Intient clinical platform, which integrates internal and external clinical data to accelerate drug development insights.

Accenture Life Sciences, a technology consulting firm, announced that its artificial intelligence​ (AI) clinical data collection and management tool, Intient, is being used by Bayer.

The platform, which went live at Bayer earlier this year, uses cloud-based technology developed by Oracle to enable the collection of internal and external clinical data​ into a single data management and storage platform.

As a result, Intient has the potential to create actionable insights to accelerate drug development and improve patient outcomes.

Under the collaboration agreement between Bayer and Accenture, the former company has also joined the Life Sciences Cloud Coalition​, a group of businesses built by Accenture and Oracle, to link biopharmaceutical companies willing to share their clinical data.

A spokesperson for Accenture told us “With the addition of Bayer, we have already seen a resounding commitment to collaboration with their peers in industry.”

“Bayer brings a global, patient-centric approach to their clinical development processes and have been transparent in their sharing of processes and best practices,”​ the spokesperson added.

Members of the Life Sciences Cloud Coalition include Pfizer, Eli Lilly, Bayer, Merck, Novo Nordisk and GlaxoSmithKline.

The aim of the coalition, according to Accenture, is to enable ‘pre-competitive’ collaboration between companies and support quick and cost-effective advancement of clinical development.

“The future of R&D is bright when leading organizations come together to solve for patients’ greatest needs,”​ commented Mike Stapleton, a managing director in Accenture’s Life Sciences practice.

Related topics: Clinical Development, Data management

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more